

Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP) is a rare disease that, when left untreated leads to a 95% morbidity rate. However, 80-90% of patients that receive treatment respond favorably. In this Phase III study, Pharm-Olam International is partnering with a progressive sponsor company to assist in finding a better solution for suffering with TTP.

Study Overview

A Phase III study for the treatment of Thrombotic Thrombocytopenic Purpura (TTP).

Therapeutic Area

Hematology

Patient Population

130+

Sites & Locations

91+ Sites across 25 countries in Asia, Eastern and Western Europe and North America

Services Provided

- Site Identification & Selection
- Regulatory
- Clinical & Medical Monitoring
- Project Management
- Medical Writing

Status

Enrollment completed

Experience & Insights

Hematology/Oncology trials represent 25% of Pharm-Olam's total study experience portfolio. Our proven methodologies, global reach and ability to enroll hard to find patients make Pharm-Olam uniquely suited to handle complex, timeline-driven development programs. With disease states where symptoms can be subtle, the identification of investigator sites that can easily identify the disease symptoms is crucial in the patient identification and enrollment processes. Our global network of investigators and in-country staff ensures that your trial meets even its most aggressive and critical timelines, on budget and within scope.

For more information about Pharm-Olam, please visit www.pharm-olam.com

About Pharm-Olam International

A multinational Contract Research Organization (CRO), Pharm-Olam offers comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering high-quality data, achieving targeted enrollment and meeting projected timelines.

Pharm-Olam makes clinical research....**Easy As I, II, III, IV™**.

